HIF-2α-IN-17 

HIF-2α-IN-17 is a selective hypoxia-inducible factor 2α (HIF2α) inhibitor that binds to the PAS-B domain of HIF2α. HIF-2α-IN-17 disrupts the interaction between HIF2α and the molecular chaperone Hsp70, leading to proteasomal degradation of HIF2α. HIF-2α-IN-17 exhibits antitumor activity and induces apoptosis in cancer cells. HIF-2α-IN-17 is applicable for research on cancers such as clear cell renal cell carcinoma^[1].

HIF-2α-IN-17 (Compound-c2) (0-30 μM; 24 h) selectively inhibits the viability of VHL-deficient clear cell renal cell carcinoma (ccRCC) cell lines (786-O, A498), with no effect on VHL-positive Caki-1 cells or normal HEK293 cells^[1].
HIF-2α-IN-17 (5-30 μM; 24 h) induces apoptosis in 786-O cells by activating caspase-3 and caspase-7^[1].
HIF-2α-IN-17 (0-30 μM; 8-24 h) suppresses the transcriptional activity of HIF2α and reduces the expression levels of HIF2α target genes (VEGF, NDRG2, CCND1, GLUT1) in 786-O cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

311.31

C₁₇H₁₄FN₃O₂

861212-49-9

CCN1C(NC(C2=CC=C(F)C=C2)=O)=C3C=CC=CC3=NC1=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Heritz JA, et al. Targeting and dissociating HIF2α from the molecular chaperone Hsp70 triggers apoptosis in kidney cancer. Commun Med (Lond). Published online January 12, 2026.  [Content Brief]